Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HCN1 | O60741 | 1/20 | 0.36 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197466 | 1.00 | MEN1 (0.39) | MEN1KMT2ASLC6A9NPC1HCN1 | |
| SCHEMBL28151536 | 1.00 | MEN1 (0.39) | MEN1KMT2ASLC6A9NPC1HCN1 | |
| SCHEMBL24357949 | 0.97 | MEN1 (0.37) | MEN1KMT2ASLC6A9NPC1HCN1 | |
| SCHEMBL10865041 | 0.95 | SLC6A9 (0.38) | MEN1KMT2ASLC6A9NPC1HCN1 | |
| SCHEMBL26499242 | 0.92 | MEN1 (0.33) | MEN1KMT2ASLC6A9NPC1HCN1 | |
| SCHEMBL12717845 | 0.92 | SLC6A9 (0.32) | MEN1KMT2ASLC6A9 | |
| SCHEMBL18180585 | 0.90 | SLC6A9 (0.37) | MEN1KMT2ASLC6A9OPRM1OPRK1 | |
| SCHEMBL25558801 | 0.87 | — | — | |
| SCHEMBL25165171 | 0.87 | — | — | |
| SCHEMBL13197467 | 0.84 | SIGMAR1 (0.44) | KMT2ASLC6A9HCN1HCN4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109000-B1 | Polymer having polymerizable group, polymerizable composition, planographic printing plate precursor, and planographic printing method using the same | FUJIFILM CORP (JP) | 2017-02-22 | — | — | EP | disclosed |
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | MEN1 3066/4885KMT2A 2104/4885SLC6A9 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.